Silo Pharma, INC Form 4 insider transactions

Silo Pharma's CEO and Director, Eric Weisblum, increased his direct beneficial ownership of common stock through open market purchases.

Silo Pharma CEO Eric Weisblum increased his direct ownership in the company by purchasing 2,000 shares of common stock over two days in November 2025.

Silo Pharma's CEO, Eric Weisblum, increased his direct ownership in the company by purchasing 12,000 shares of common stock over two days in November 2025.

Silo Pharma, Inc.'s Chief Executive Officer and Director, Eric Weisblum, acquired an additional 10,000 shares of common stock on May 27, 2025, increasing his direct beneficial ownership to 197,932 shares.

Silo Pharma, Inc. Director Wayne Linsley was granted 50,000 stock options with an exercise price of $0.429, vesting one year from the grant date, under the company's 2020 Omnibus Equity Incentive Plan.

Silo Pharma, Inc. Director Kevin Munoz was granted 50,000 stock options with an exercise price of $0.429, vesting in one year, as part of the company's 2020 Omnibus Equity Incentive Plan.

Silo Pharma, Inc.'s Chief Financial Officer, Daniel E. Ryweck, was granted 50,000 stock options with an exercise price of $0.429, vesting on the one-year anniversary of the grant date.

Silo Pharma, Inc. CEO Eric Weisblum has been granted 200,000 stock options with an exercise price of $0.429, vesting one year from the grant date.

Silo Pharma, Inc. director Jeff Pavell was granted 50,000 stock options with an exercise price of $0.429, vesting one year from the grant date of May 23, 2025.

Silo Pharma's CEO and President, Eric Weisblum, purchased 2,500 shares of common stock at a price of $0.8387 per share.

Silo Pharma's CEO, Eric Weisblum, has acquired 5,000 shares of common stock through open market purchases over two days.

Silo Pharma's CEO, Eric Weisblum, reported purchasing common stock in two transactions on June 11 and June 12, 2024.

Silo Pharma's CEO, Eric Weisblum, reported purchasing common stock in the company on April 4th and 5th, 2024.

Silo Pharma's CEO, Eric Weisblum, recently purchased additional shares of the company's common stock in two separate transactions.